Wel­come to 'tis­sue ther­a­peu­tics’: Dave Lennon’s $110M new ven­ture will im­plant ‘hap­py cells’ that ‘sur­vive and thrive’

You’ve heard of cell ther­a­pies. You’ve cer­tain­ly heard of gene ther­a­pies. But have you heard of tis­sue ther­a­peu­tics?

Just in time for May flow­ers, a biotech two decades in the works — longer if you count the co-founders’ first aca­d­e­m­ic en­coun­ters as grad stu­dent peers in the mid-1990s — has sprung from the shad­ows of Cam­bridge, MA to in­tro­duce the world to what it deems an “ex­cit­ing new pil­lar with­in the re­gen­er­a­tive med­i­cine field.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN